 CARMIEL, Israel, Aug. 16, 2021 PRNewswire -- Protalix BioTherapeutics, Inc. NYSE American: PLX TASE: PLX, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today reported financial results for the second quarter ended June 30, 2021 and provided a financial and business update. We continue to work closely with the FDA to address the issues raised in the Complete Response Letter received in April for PRX-102 for the proposed treatment of adult patients with Fabry disease, said Dror Bashan, Protalixs President and Chief Executive Officer. 